Global Dry Powder Inhaler Market, By Product (Capsule Based Devices, Blister Based Devices, Reservoir/Cartridge Based Devices, and Others), By Indication (Bronchitis, Chronic Obstructive Pulmonary Diseases (COPD), Asthma, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2029

Dry powder inhaler (DPI) is a device used to deliver medication to lungs in the form of powder. Dry powder inhaler is used to treat respiratory diseases such as asthma, bronchitis, emphysema, etc. DPI are better alternatives to conventional inhalers such as metered-dose inhalers. The dry powder inhaler is breath activated, where the drug or medicine is released to lungs only after taking a fast deep breath through inhaler.

Increasing occurrence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, etc. across the globe is a major factor driving growth of the global dry powder inhaler market. Also, cost effective devices demands for treatment of respiratory disorders among the users is another factor likely to grow the target market. Nonetheless, high cost of device is a major factor restraining growth of the global dry powder inhaler market. In totaling, strict government guidelines related to device approval is other factor expected to restrain growth of the global dry powder inhaler market. Progressions like growth of dry powder inhaler that offers high dose of medications into lungs, is likely to form revenue opportunities to companies, operating in the target market.

The global dry powder inhalers market has been segmented based on product, distribution channel, and region. In terms of product type, the global market can be categorized into capsule based devices, blister based devices, reservoir/cartridge based devices, and others. The capsule based devices segment is anticipated to govern the target market during the forecast period, due to increase in number of manufacturers contributing diverse products in the segment. On the basis of indication, the target market can be classified into bronchitis, chronic obstructive pulmonary diseases (COPD), asthma, and others. The asthma section accounted for the major share due to increase in air pollution levels across the world and rise in incidence of asthma especially in developed countries. On the basis of distribution channel, the global dry powder inhaler market can be divided into hospital pharmacies, online pharmacies, retail pharmacies, and drug stores. On the basis of region, the global dry powder inhalers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America being a dominating player among the all other regions due to high pervasiveness of chronic respiratory diseases including asthma and allergic asthma in the U.S. and auspicious compensation policies for dry powder inhalers in the country. Countries in Europe region such as Germany, the U.K., Russia, and France also reported higher prevalence of respiratory diseases including asthma, higher per capita health care spending, and increase in number of market players introducing new products in the market. In Asia Pacific region, there is a significant growth in the geriatric population which is increasing the demand for the dry powder inhalers.

Key players operating in the global dry powder inhalers market are Cipla Inc., GlaxoSmithKline Plc., Teicos Pharma Ltd., Presspart Manufacturing Ltd., Beximco Pharma Ltd., Catalent, Inc., Hovione FarmaCiencia SA., AstraZeneca Plc., Bespak Europe Ltd., and SRS Pharmaceuticals Pvt. Ltd.